3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
9
Neoplasm Metastasis
4
Sarcoma
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Glioma
3
Breast Neoplasms
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Ependymoma
2
Colorectal Cancer Metastatic
2
Central Nervous System Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Interventions
Gemcitabine
3
pembrolizumab
2
napabucasin
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
130-nm albumin-bound paclitaxel
2
trametinib
1
siltuximab
1
repotrectinib
1
pralsetinib
1
lutetium Lu 177 dotatate
1
linifanib
1
durvalumab
1
dabrafenib
1
copper dotatate CU-64
1
cobimetinib
1
capmatinib
1
atezolizumab
1
Vemurafenib
1
Pemetrexed
1
Paclitaxel
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Immunotherapy
1
HhAntag691
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Vemurafenib
×
Gastrointestinal
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled